Logo-jcvtr

J Cardiovasc Thorac Res. 2017;9(3): 179-182. doi: 10.15171/jcvtr.2017.31
PMID: 29118953        PMCID: PMC5670342

Short Communication

The role of preoperative sildenafil therapy in controlling of postoperative pulmonary hypertension in children with ventricular septal defects

Hamid Bigdelian 1, Mohsen Sedighi 2,3 *

Cited by CrossRef: 10

1- Golovenko O, Lazorhyshynets V, Prokopovych L, Truba Y, DiSessa T, Novick W. Early and long-term results of ventricular septal defect repair in children with severe pulmonary hypertension and elevated pulmonary vascular resistance by the double or traditional patch technique. 2022;62(2) [Crossref]
2- Beghetti M, Gorenflo M, Ivy D, Moledina S, Bonnet D. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO‐sGC‐cGMP pathway. Pediatric Pulmonology. 2019;54(10):1516 [Crossref]
3- Awad A, Gad E, Abdelgalil M, Elsaeidy A, Ahmed O, Elbadawy M. Sildenafil for congenital heart diseases induced pulmonary hypertension, a meta-analysis of randomized controlled trials. BMC Pediatr. 2023;23(1) [Crossref]
4- Bigdelian H, Ghaderian M, Sedighi M. Surgical repair of Tetralogy of Fallot following primary palliation: Right ventricular outflow track stenting versus modified Blalock-Taussig shunt. Indian Heart Journal. 2018;70:S394 [Crossref]
5- Fikri Y, Mulia E, Nugroho F. Preoperative Sildenafil in Pediatric Patients Undergoing Congenital Heart Surgeries: A Systematic Review and Meta-Analysis. Semin Cardiothorac Vasc Anesth. 2023;27(4):252 [Crossref]
6- Palladino-Davis A, Davis C. Outcomes of infants and children undergoing surgical repair of ventricular septal defect: a review of the literature and implications for research with an emphasis on pulmonary artery hypertension. Cardiol Young. 2020;30(6):799 [Crossref]
7- Patel R, Thingnam S, Mishra A, Rohit M, Upadhyay V, Halder V, Bansal V. Benefits of perioperative sildenafil therapy in children with a ventricular septal defect with pulmonary artery hypertension on early surgical outcomes. J Card Surg. 2020;35(12):3302 [Crossref]
8- Islas J, Moreno-Cuevas J. A MicroRNA Perspective on Cardiovascular Development and Diseases: An Update. IJMS. 2018;19(7):2075 [Crossref]
9- Cao F, Wu K, Zhu Y, Jiang J, Zhang G, Liu J, Xiao P, Tian Y, Zhang W, Zhang S, Hou F, Bao Z. Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis. Front Cardiovasc Med. 2023;9 [Crossref]
10- Usmani S, Hasan S, Ali S, Ahmed S, Pervez N, Danial M, Khan O, Tucker D, Zubair M. Perioperative sildenafil therapy in pulmonary hypertension associated with congenital cardiac disease: An updated meta-analysis. Asian Journal of Surgery. 2024;47(6):2551 [Crossref]
11- Shams K, Ellahony D, Halima A, Elzayat R. Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients. Egypt Heart J. 2024;76(1) [Crossref]